Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT: Ipragliflozin for Prevention of Atherosclerosis in Type 2 Diabetes
jRCTs071180041Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of ipragliflozin in type 2 diabetes mellitus (T2DM) and Carotid artery disease (CAD) (2 arms), sponsored by Astellas Pharma. Started Sep 2015; status: completed.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)Carotid artery disease (CAD)
Beyond the preview
Go deeper on jRCTs071180041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180041.